B-lymphocyte antigen CD20 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13B-lymphocyte antigen CD20 shows approved-linked disease relevance led by non-Hodgkins lymphoma. 5 more disease programs remain visible in the same review block. 15 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P11836. Start with non-Hodgkins lymphoma, then reuse UniProt P11836 as the stable protein anchor across project notes and exports.
Start with non-Hodgkins lymphoma, then reuse UniProt P11836 as the stable protein anchor across project notes and exports.
B-lymphocyte antigen CD20 shows approved-linked disease relevance led by non-Hodgkins lymphoma. 5 more disease programs remain visible in the same review block. 15 linked drugs remain visible in the same block.
Start review with non-Hodgkins lymphoma because it currently carries approved-linked support. Linked drugs include EPCORITAMAB, GLOFITAMAB, MOSUNETUZUMAB, MT-3724. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyB-lymphocyte antigen CD20
Review this target as B-lymphocyte antigen CD20, mapped to UniProt P11836. Sequence length is 297 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats B-lymphocyte antigen CD20 as ChEMBL target CHEMBL2058, mapped to UniProt P11836. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether B-lymphocyte antigen CD20 is the right protein anchor across sources, using UniProt P11836 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why non-Hodgkins lymphoma is currently framed as approved-linked support. It currently carries 15 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | B-lymphocyte antigen CD20 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P11836 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | B-lymphocyte antigen CD20 |
| UniProt Accession | P11836 |
| Component Type | Protein |
| Sequence Length | 297 aa |
B-lymphocyte antigen CD20
Review this target as B-lymphocyte antigen CD20, mapped to UniProt P11836. Sequence length is 297 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
B-lymphocyte antigen CD20 shows approved-linked disease relevance led by non-Hodgkins lymphoma. 5 more disease programs remain visible in the same review block.
Start review with non-Hodgkins lymphoma because it currently carries approved-linked support. Linked drugs include EPCORITAMAB, GLOFITAMAB, MOSUNETUZUMAB, MT-3724. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.